Kornimate/medical-research-clean huggingface dataset:
nasal obstruction and olfactory losses

Conditions: Nasal Obstruction

Summary: about 13% of us adults, some 30 million people, suffer from nasal sinus disease. although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. the proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.

nasal sinus disease is one of the most common medical conditions in the us, affecting an estimated 13% of adults, or some 30 million people, and responsible for $5.8 billion in health care expenditures annually (national health interview survey 2009, cdc). nasal obstruction and smell loss are two of the major symptoms of the disease; however, the field currently lacks a clear, objective understanding of the mechanisms causing these symptoms, which thwarts effective treatment. for example, patients' complaints of nasal obstruction correlate poorly or inconsistently with objective measurements of actual physical obstruction. without validated clinical tools, the current treatment of these symptoms relies primarily on the patient's subjective feedback and the doctor's personal training and experience, which can lead to inconsistent and unsatisfactory outcomes. through a series of preliminary studies, the investigators demonstrated that the symptom of nasal obstruction may be caused not by obstruction per se but by poor sensing of airflow during breathing or sensing may be worsened by impaired trigeminal function. however, which trigeminal sensory regions and what nasal airflow anomalies are most critical in disrupting the sensing of airflow are still unknown. in aim 2, the investigators will investigate the efficacy of a novel patent-pending "nasal aid" to improve patients' symptoms by modulating nasal airflow and trigeminal sensory feedback and to improve future treatment outcomes based on what the investigators have learned and will continue to learn about the airflow trigeminal perception mechanisms. the outcomes from this research may potentially validate several novel clinical tools to better identify factors that most affect patients' obstructive symptoms and to relieve symptoms by modulating nasal airflow patterns. the ultimate goal is to assist patients and clinicians in planning effective, well-informed, personalized treatment strategies, potentially saving millions of healthcare dollars annually while improving patient satisfaction.

Eligibility criteria:
inclusion criteria: 1. smell loss complaints 2. nasal obstruction exclusion criteria: 1. congenital olfactory losses 2. nasal polyps, blocking the olfactory cleft 3. significant atrophy 4. cystic fibrosis 5. wegeners or any other connective tissue disorder 6. head trauma
nicotine patch as an analgesic adjuvant after surgery

Conditions: Pain

Summary: effect of nicotine patch as an adjutant for acute pain after surgery.

this is a dose finding trial for nicotine patches as analgesics. doses used are 5mg/ 10mg/ 15mg or placebo. primary outcome variable is reported pain score (vas), secondary is morphine pca utilization, nausea, sedation, and hemodynamic changes.

Eligibility criteria:
inclusion criteria: * adult asa 1-2 exclusion criteria: * cardiovascular disease * former smoker * pregnant * nursing * asthma

Keywords: acute pain nicotine nausea sedation
erector spinae plane block vs. ipack block with adductor canal block for total knee arthroplasty

Conditions: Knee Osteoarthritis; Knee Pain Chronic; Knee Arthritis

Summary: effect of erector spinae plane block and ipack block with adductor canal block on pain management, and nlr and plr following knee arthroplasty

knee arthroplasty is one of the most common orthopedic procedures, especially in elderly patients, due to the deformation of joints. patients may complain of severe pain due to surgical trauma and prosthesis. regional anesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects. in recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasized. however, very few studies have evaluated the effect of various methods of anesthesia on the nlr.

Eligibility criteria:
inclusion criteria: * patients with asa classification i-iii, * aged 20-100 years, * scheduled for knee arthroplasty under spinal anaesthesia exclusion criteria: * patients who have a history of bleeding diathesis, * take anticoagulant therapy, * have a history of chronic pain before surgery, * have multiple trauma, * cannot assess their pain (dementia), * have been operated on under general anaesthesia, * have an infection in the area * do not accept the procedure
the duration study

Conditions: Anemia

Summary: the purpose of this study is to compare the efficacy of epoetin alfa (procritâ®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (procritâ®) treatment in patients with cancer who are anemic.

the purpose of this study is to evaluate hematologic response in patients receiving epoetin alfa (procrit®) therapy for persistent chemotherapy-induced myelosuppression (anemia) after completion of chemotherapy administration as compared to patients who do not receive weekly epoetin alfa (procrit®) immediately after cessation of chemotherapy. further, the duration of treatment necessary to achieve these endpoints will be studied. a no/delayed epoetin alfa (procrit®) treatment control (whereby patients in the control group will receive epoetin alfa (procrit®) if their hb decreases to \< 10g/dl during the study) will be used to establish the frequency and magnitude of changes in clinical end points that may occur when epoetin alfa (procrit®) treatment is not continued (or started) for patients with residual myelosuppression after chemotherapy administration has ended. a 2:1 randomization will be used to give every patient a greater chance to receive immediate treatment (66.6% epoetin alfa (procrit®) treatment vs. 33.3% no/delayed epoetin alfa (procrit®) treatment). the study will be powered to show differences between the two groups in hematologic response. in this study, the hematologic response is defined as the proportion of patients who are transfusion-free and are able to maintain their mean hb level at \>= 11 g/dl during the study without a hb drop to \<= 10 g/dl and/or transfusion. the study hypothesis was that immediate epoetin alfa (procrit®) treatment would be more effective in treatment of anemia than no/delayed epoetin alfa (procrit®) treatment in patients with cancer and persistent chemotherapy-induced anemia. patients will be randomized 2:1 to receive epoetin alf or no epoetin treatment. the starting dose will be 40,000 units weekly (qw) or the dose they were on prior to the study (30,000-60,000 units qw). if the hb level decreases to \<= 10 g/dl, procrit will be initiated at a dose of 40,000 units qw.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of non-myeloid malignancy * baseline hemoglobin value \>= 11 g/dl and \<= 12 g/dl unrelated to transfusion * female patients with reproductive potential must have a negative serum pregnancy test at screening. patients must have signed an informed consent exclusion criteria: * uncontrolled hypertension * history (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder * transfusion within 28 days prior to first dose * planned myelosuppressive chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry.

Keywords: anemia neoplasm hemoglobin level
a clinical study of mk-4482 in chinese healthy male participants (mk-4482-009)

Conditions: Healthy

Summary: the goal of the study is to learn what happens to mk-4482 after single and multiple doses in healthy chinese participants over time. researchers also want to learn about the safety of mk-4482, including how well people tolerate it.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: - has a body mass index (bmi) of 19 to 24 weight (kg)/height (m)2, inclusive, and body weight of ≥ 50 kg at the screening visit. exclusion criteria: the main exclusion criteria include but are not limited to the following: * has a history of clinically significant abnormalities or diseases. * has history of cancer. * has a history of significant multiple and/or severe allergies. * had any major surgery. * has participated in another investigational study within 3 months prior to the screening visit.

Keywords: coronavirus disease (covid-19)
the effect of additional transforaminal epidural blocks in percutaneous epidural neuroplasty

Conditions: Lumbar Spinal Stenosis

Summary: percutaneous epidural neuroplasty (pen) is an effective interventional treatment for radicular pain. but in some cases with wire catheter like racz catheter, contrast runoffs were not shown to the foramen. this study will show that contrast runoff will affect the results of pen and in cases which contrast runoff are not shown, additional transforaminal epidural blocks will affect the results of pen by reviewing medical record, retrospectively.

medical records will be investigated in cases of pen with wire type catheter from may 2016 to august 2018. about one hundred cases will be enrolled. analysis will be performed. it will be compared 1) success rate of runoff group and nonrunoff group in lumbar spine, 2) success rate of runoff group and nonrunoff-nontransforaminal group in lumbar spine. 3) success rate of runoff group with nonrunoff-transforaminal group and nonrunoff-nontransforaminal group in lumbar spine. 4) success rate of nonrunoff-transforaminal group and nonrunoff-nontransforaminal group in lumbar spine.

Eligibility criteria:
inclusion criteria: * 20 to 80 years old * patients with a herniated disc, spinal stenosis * patients with chronic low back pain and lower extremity pain who did not respond to lumbar epidural steroid injections * patients who are performed percutaneous epidural neuroplasty with wire type catheter. exclusion criteria: * incomplete medical record * contraindication to percutaneous epidural neuroplasty
safety and efficacy of intermittent renal replacement therapy using citrasate in critically-ill patients

Conditions: Acute Kidney Injury; Chronic Kidney Infection

Summary: renal replacement therapy (rrt) needs an extracorporeal circulation to conduct blood to the dialysis membrane and driving back to the patient. this extracorporeal circulation induces inevitably a risk of coagulation activation and premature clotting of the circuit. heparin is thereby commonly used to prevent such thrombosis but exposed patient to risk of hemorrhage. this risk of hemorrhage may be important in icu population, particularly in severe trauma patients. the calcium is an important determinant of coagulation cascade. the use of specific citrate enriched dialysate without calcium (citrasate®) allows to suddenly lower the calcium concentration in extracorporeal plasma, leading to a regional ineffectiveness of clotting and limited heparin needs. this low calcium plasmatic concentration into the extracorporeal circulation has however to be normalized to not generate a systemic hypocalcemia. in our icu, a local calcium substitution protocol based on dialysate flow is used in clinical practice. commonly used in our unit, there is a lack data to evaluate the citrasate dialysate in a critical population. the aim goal of our study will be to assess safety and efficacy of intermittent renal replacement therapy using citrasate® in critically-ill patients.

this is a retrospective descriptive study. the included patients will be those who had a sustained low efficiency dialysis using citrasate® dialysate in chu lapeyronie in montpellier, france between 01/01/2019 and 31/12/2021 using pmsi code, we estimate that 61 patients could be enrolled in this period and each patient could be almost 6 dialysis session. we estimate we could analyzed 300 to 350 sessions. this sample must be confirmed by the opening of medical records. a data collection will be focused on the rrt parameters, clinical complications until icu discharge and outcome, extracted from medical records. the main endpoint will be to determine the prevalence of ionized calcium troubles (hypocalcemia \ 1,4 mmol/l) per and post dialysis using citrasate® with our restitution protocol, and their therapeutic consequences. the secondary endpoints will be to describe the efficacy of citrasate® with our restitution protocol during rrt meant by an optimal dialysis dose and the absence of premature clotting of the circuit.

Eligibility criteria:
inclusion criteria: * age ≥18 years * patient underwent a rrt in the dar lapeyronie (chu montpellier) between the 01/01/2019 and the 31/12/2021 exclusion criteria: * patient underwent rrt without citrasate® protocol * lack of data * ethical limitation

Keywords: renal replacement therapy citrasate
ocean registry: obesity and clock for elegant aging registry

Conditions: Obesity; Circadian Dysregulation; Aging; Cardiovascular Disease

Summary: this study aims to study the relationships between obesity, circadian rhythm, and aging. the investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. the cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.

the objective of this observational study is the follow-up of 2000 adult obesity (bmi ≥ 35 and 24-35 kg/m2) and non-obese subjects with annual follow-up for 10 years. clinical data, biochemistry, and biological samples (serum, dna, rna, white blood cells) will be collected and stored. adipose tissues will be collected if participants received liposuction, plastic surgery, bariatric surgery, dermatological procedure, intra-abdominal operation, and cardiovascular surgery. questionnaires will be obtained with special nurse including sleep quality, chronotypes, and circadian activities. during follow up period, major adverse cardiovascular events will be monitored. the investigators anticipate that the results generated from the study will provide valuable data to a better understanding of the relationships between obesity, circadian rhythm, and aging.

Eligibility criteria:
inclusion criteria: * age ≥ 20 years old * body mass index ≥ 24 kg/m2 * for normal subjects, body mass index \< 24 kg/m2 exclusion criteria: * no inform consent * use of steroid medications * severe systemic diseases or organ failure with estimated life expectancy of 6 months or less
use of the quantra qplus sytem in cardiac surgery

Conditions: Cardiovascular Diseases

Summary: single center retrospective study evaluating the impact of using the quantra qplus system to guide transfusion decisions on postoperative outcomes in patients undergoing cardiac surgery.

yavapai regional medical center (yrmc) implemented the quantra qplus system to aid in their efforts to effectively reduce the transfusion rate of allogenic blood products and improve outcomes in patients undergoing cardiac surgery. use of the quantra to guide decisions related to the use of blood products in cardiac surgery patients began in 2019. in this retrospective study, yrmc evaluated the impact of using the quantra qplus system to guide transfusion decisions on postoperative outcomes in patients undergoing cardiac surgery.

Eligibility criteria:
* pre-quantra group: all consecutive patients undergoing cardiac surgical procedures during the period from january 2019 to september 2019 (n=64) * post-quantra group: all consecutive patients undergoing cardiac surgical procedures during the period from may 2020 to april 2021 (n=64)

Keywords: cardiac surgery quantra viscoelastic testing coagulation qplus
effects of routine physical therapy with and without neurodevelopmental technique on gmf, spasticity and hrqol in diplegic cp

Conditions: Cerebral Palsy

Summary: the aim of this study is to investigate the effects of routine physical therapy with and without neurodevelopmental technique on gross motor function, spasticity and health related quality of life in diplegic cerebral palsy.

the neurological illness known as cerebral palsy is caused by damage to the growing brain and therefore is indicated by anomalies of muscle strength, mobility, and motor functions. cerebral palsy affects posture, muscle tone, and movement development. neurodevelopmental technique and routine physical therapy are considered to be effective in treatment of cerebral palsy. this study will investigate the combined effects of neurodevelopmental technique and routine physical therapy versus routine physical therapy on gross motor function, spasticity, and health related quality of life in diplegic cerebral palsy.

Eligibility criteria:
inclusion criteria: * patients with an age of 8 to 18 years of both genderswith confirm diagnosis of diplegic cerebral palsy * patients could ambulate functionally * patients having limited or no prior exposure to ndt * individuals with mild to moderate diplegic cerebral palsy, based on established classification scales (gmfm grade i-iii) exclusion criteria: * patients with other motor or sensory dysfunctions and unable to understand and obey commands * patient undergone any orthopedic surgery that was ought to treatspasticity * patients with spasticity level 4-5 according to modified ashworth scale * patients with botulinum toxins type a injection within last 6 months

Keywords: cerebral palsy gross motor function neurodevelopmental technique health realted quality of life routine physical therapy
protein sorbent properties of montmorillonite in vitro and in vivo models

Conditions: Urea Cycle Disorders, Inborn; Other Metabolic Diseases

Summary: montmorillonite (mont) is a phyllosilicate layered mineral with unique physicochemical properties, such as swelling and cation exchange capability. the aim of this project is to study, in healthy volunteers, the in vivo ability of mont to reduce protein intestinal uptake. furthermore, the study analyzed in vitro the mont ability of immobilizing proteins.

montmorillonite (mont) is a phyllosilicate layered mineral; chemically it is hydrated sodium calcium aluminium magnesium silicate hydroxide. potassium, iron, and other cations are common substitutes and the exact ratio of cations varies with source. due to its unique physicochemical properties, such as swelling and cation exchange capability, as well its mechanical and thermal stability, mont can be efficiently used as matrix for immobilization of proteins with high molecular weight (e.g. albumin) and proteins with low molecular weight (e.g.aflatoxines). therefore, mont is used for therapeutic purposes, in pharmaceutical formulations and in food preparations. in vitro assays made in our laboratory, showed that mont absorbs, in stable manner, alimentary proteins: beta-lactoglobulins, alfa lactoalbumines and the ratio mont-protein (w/w) 1:3, 1:5, 1:15, results in the protein capture of 50, 27, 0 % of proteins respectively. the aim of this project is to study, in healthy volunteers, the in vivo ability of mont to reduce protein intestinal uptake evaluated with the blood mont- protein ratio. furthermore, the study analyzed in vitro the mont ability of immobilizing proteins at different ratio (w/w) 1:3, 1:5, 1:15.

Eligibility criteria:
inclusion criteria: * healthy volunteers (12m, 13 f, 25-30 years). fasting from morning exclusion criteria: * not defined

Keywords: montmorillonite, proteic diet, in vitro and in vivo models
application of a dental-dedicated mri in the diagnosis of temporomandibular joint disorders, tissue alterations related to third molars, periapical and periodontal inflammatory diseases, and implant treatment planning

Conditions: TMJ; Apical Periodontitis; Periodontal Inflammation; Retained Tooth; MRI

Summary: the aim of the present study is to show that the use of 0.55t mri combined with a "dental" coil produces images of sufficient diagnostic value to assess areas of interest in dentistry, and to compare mr images to traditional, dental-oriented radiographic images for diagnostic purposes.


Eligibility criteria:
inclusion criteria (one of the following): * referred for cbct imaging of at least one tooth for endodontic reasons * referred for intra-oral and/or panoramic imaging covering at least one molar tooth for periodontal reasons * referred for cbct imaging of the tmj (bilaterally) * referred for panoramic imaging of the third molar (retained/semi-retained, uni- or bilateral), prior to treatment planning * referred for cbct imaging prior to implant treatment exclusion criteria: * younger than 18 years * unable to give consent * pregnant * pronounced claustrophobia * pacemakers or implanted defibrillators * metal shrapnel injuries of the eyes or mri incompatible metallic inclusions or implants large tatoos * non-removable piercings
long-term follow-up of gene therapy for apoe4 homozygote alzheimer's disease

Conditions: Alzheimer Disease

Summary: the primary purpose of this long-term follow-up study is to assess the long-term safety profile of apoe4 homozygote participants who were administered gene therapy (lx1001) for the treatment of alzheimer's disease in study lx100101. a secondary objective is to assess the biomarker as shown by the conversion of csf apoe isoforms from apoe4 to apoe2-apoe4. additional secondary outcomes include amyloid pet scan, csf markers (including aβ42, aβ42/aβ40 ratio t--tau, and p-tau), and quantitative mri (and other biomarkers that may be informative for this therapeutic approach). other secondary objectives include instruments to assess cognitive and clinical ad and to evaluate if treatment with aavrh.10hapoe2 improves brain tau pathology with tau pet scan (lx1001-01 cohorts 3 and 4 only).

this is a long-term follow-up study to evaluate the safety following lx1001, a gene therapy, for participants who are apoe4 homozygotes with clinical diagnoses varying from mci or dementia due to ad who have previously received lx1001. study lx1001-01 was designed to assess the safety of lx1001 at 4 ascending doses (1.4 × 1010, 4.4 × 1010, 1.4 × 1011 gene copy \[gc\]/ml csf and 1.4 x 1014 \[fixed dose\]) as per droplet digital polymerase chain reaction methodology, with each group consisting of approximately n=3-5 individuals for a total of approximately 15 participants for the entire study. in this study, participants who have received lx1001 in the parent protocol (lx1001-01) will be followed for up to 260 weeks post gene therapy administration to assess the safety and efficacy parameters (\~208 weeks within this study)

Eligibility criteria:
inclusion criteria: * participants who received lx1001 in study lx1001-01 exclusion criteria: * participants with any clinically significant medical condition that, in the opinion of the investigator, would pose a risk to participant safety * participants who agree not to post their personal medical data in relation to this study or any study information online, including social media sites, until all participants have completed all lx1001 clinical studies, including long-term follow-up.